DT-216P2
DTX-216P2-011
Phase 2 small_molecule active
Quick answer
DT-216P2 for Friedreich Ataxia is a Phase 2 program (small_molecule) at Design Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Design Therapeutics
- Indication
- Friedreich Ataxia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active